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Introduction
•

•

•

•

Immune checkpoint blockade (ICB) therapies
have shown promising results in treating a
variety of cancer types. However, the median
overall survival of triple negative breast cancer
(TNBC) remains very low.
A new protein B7 homolog 3 (B7H3), or CD276,
was found to be overexpressed in many cancer
cells and have little to no expression on normal
cells.
It initially was characterized as a costimulatory
molecule promoting the activation of T cells but
is now understood to act mainly as a coinhibitory
molecule of the immune system.
B7H3’s mechanism of action and receptor
remain uncharacterized, but its preference for
malignant cells offers hope for a new therapeutic
approach with less toxicity and more efficiency.
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To determine the expression of B7H3 in
primary TNBC tumors and measure the effect
of novel anti-B7-H3 antibodies in the
activation of NK cells and T lymphocytes
against TNBC
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Fig. 1. IHC assay shows higher B7H3 expression in tumor tissue than normal mammary tissue
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Fig. 2. Addition of anti-B7H3 monoclonal antibodies promotes NK cell-mediated apoptosis in HCC38 RFP
cells. More apoptosis can be seen with treatment of NK:TNBC cell ratio 8:1 + 10ug/ml mAb (yellow)
versus control IgG (green) at 8 hours (b)
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Methods
•

•

•

•

We performed immunohistochemistry to
investigate B7H3 expression in TNBC primary
tumors (n=49) and adjacent normal mammary
tissue (n=30). The data was acquired and
quantitated using Vectra-Polaris®, multispectral imaging system
Natural killer (NK) cells and T lymphocytes
were isolated from buffy coats of healthy
donors by Ficoll density gradient
centrifugation.
RFP-tagged B7H3+/- TNBC cell lines were cocultured with primary NK cells or T cells at
different immune cell to target cells ratios. The
cells were simultaneously incubated with
different concentrations of novel anti-B7H3
monoclonal antibodies (mAb) or chimeric
antibodies (chAb) against a control antibody
Immune cell-mediated apoptosis and antibodydependent cytotoxic was measured by
IncuCyte® live cell imaging system

•
•

Objective
•

Conclusions

Results

B7H3 is overexpressed in TNBC cells
compared to healthy donors, validating it as a
potential therapeutic target in patients
Activation of NK cells is evident in figure 2
as seen by the increased killing with our
novel mAb compared to IgG control
antibody. The antibody also enhanced T cell
killing by blocking B7H3 as shown in figure
4
Figure 3 demonstrates the decreasing amount
of live MCF7RFP cells as a result of
treatment with the chimeric anti-B7H3
antibody co-cultured with NK cells. This
required a much lower dose of NK cells than
the experiment with monoclonal antibodies.
This is due to the activation of the ADCC
mechanism.
The data suggests that our novel monoclonal
and chimeric B7H3 blocking antibodies
inhibit its immunomodulatory function and
activate immune cells against TNBC cells
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Fig. 3. Addition of anti-B7H3 chimeric antibodies promote ADCC in MCF7 RFP cells. A decrease in
surviving cells can be seen with treatment of NK:TNBC cell ratio of 2:1 + 5ug/ml chAb (yellow) versus
rituximab control (green) in 24 hours (b)
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Fig. 4. Addition of anti-B7H3 monoclonal antibodies promote apoptosis by T lymphocytes in HCC38 RFP
cells. An increase in killing can be seen with treatment of T cells: TNBC cell ratio of 10:1 + 10ug/ml
mAb (yellow) versus IgG control (green) in 6 hours (b).
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